…source material. The statin should be prescribed at the highest tolerated dose. When LDL C remains above target despite maximally tolerated statin therapy, ezetimibe is…

…physical activity, dietary and lifestyle measures, high intensity statin therapy, and appropriate antithrombotic treatment form the broader management framework. Response to treatment should be reviewed…

…patients at increased ASCVD risk. Ezetimibe is appropriate when the LDL C goal is not achieved with statin therapy or when statins cannot be prescribed…

…directed therapy, or when recurrent cardiovascular events occur despite such treatment. The trials did not establish a mortality benefit. Consequently, the decision to prescribe colchicine…

…C targets are not met with statins alone. PCSK9 Inhibitors: Added in cases where LDL C remains above the goal despite statin and ezetimibe therapy…

…improve or resolve after reducing the dose or stopping therapy. It is divided clinically into: Complete intolerance: inability to tolerate any dose of any statin…

…atherosclerotic vascular disease or familial hypercholesterolaemia, addition of bempedoic acid to statin therapy reduced LDL C by approximately 16.5%; the reduction in a subgroup…

…The treatment sequence is generally: High intensity statin therapy at the highest tolerated dose. Addition of ezetimibe if the LDL C target is not achieved…

…individuals at high or very high risk. Prolonged exposure to lower LDL C concentrations is associated with lower ASCVD risk. Atherogenic particle burden is not…

…High intensity statin treatment is recommended for all patients with ACS to reduce major adverse cardiovascular events. Therapy should preferably begin before planned percutaneous coronary…